Sarepta jumps into the CRISPR fray with Duke gene-editing pact
Cambridge-based Sarepta Therapeutics said Tuesday that it will seek to develop drugs for Duchenne muscular dystrophy using CRISPR/Cas9 gene-editing technology, jumping into an increasingly competitive but still uncertain field.
Sarepta (Nasdaq: SRPT) said it had reached an agreement to exclusively license technology related to CRISPR/Cas9 from Duke University. Researchers there, led by Dr. Charles Gersbach, have shown that the technology can be used in mice to remove mutated parts of genes, or exons,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Genetics | Health Management | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy